CD2 Monoclonal Antibody (TS2/18), Invitrogen™

Description

• MA0200 targets CD2 in FACS, IA, IP, and WB applications and shows reactivity with Human samples
• This antibody does not react with rat tissue in Western blot applications
• The MA0200 immunogen is human LFA-2 (CD2)
• MA0200 detects CD2 which has a predicted molecular weight of approximately 37 kDa
• This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg)
• CD2 (LFA-2) is a monomeric surface antigen (MW range 45-58 kDa) of the human T-lymphocyte lineage that is expressed on all peripheral blood T cells
• CD2 is one of the earliest T-cell markers, being present on more than 95% of thymocytes and it is also found on some natural killer cells, but not on B lymphocytes
• Monoclonal antibodies directed against CD2 inhibit the formation of rosettes with sheep erythrocytes, indicating that CD2 is the erythrocyte receptor or is closely associated with it
• The interaction between CD2 and CD58 stabilizes adhesion between T cells and antigen presenting or target cells
• Relatively low affinity of CD2 to CD58 (as measured in solution) is compensated within the two-dimensional cell-cell interface to provide tight adhesion
• Moreover, T cell activation induces increased CD2 expression and its lateral mobility, making easier contact between CD2 and CD58
• Subsequently, T cell activation causes fixation of CD58-CD2 at sites of cell-cell contact, thereby strengthening intercellular adhesion
• CD2 deficiency reduces intestinal inflammation and helps to control infection
• Diseases associated with CD2 dysfunction include penis squamous cell carcinoma and immune deficiency due to the absence of the thymus.